help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mohanty, P.
Right arrow Articles by Dandona, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mohanty, P.
Right arrow Articles by Dandona, P.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 6 2728-2735
Copyright © 2004 by The Endocrine Society

Evidence for a Potent Antiinflammatory Effect of Rosiglitazone

Priya Mohanty, Ahmad Aljada, Husam Ghanim, Deborah Hofmeyer, Devjit Tripathy, Tufail Syed, Waddah Al-Haddad, Sandeep Dhindsa and Paresh Dandona

Division of Endocrinology, Diabetes and Metabolism, State University of New York, and Kaleida Health, Buffalo, New York 14209

Address all correspondence and requests for reprints to: Paresh Dandona, M.D., Ph.D., Diabetes-Endocrinology Center of Western New York, 3 Gates Circle, Buffalo, New York 14209. E-mail: pdandona{at}kaleidahealth.org.

We have recently demonstrated a potent antiinflammatory effect of troglitazone, an agonist of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) and a partial agonist of PPAR{alpha} in both the nondiabetic obese and diabetic obese subjects. We have now investigated the antiinflammatory actions of rosiglitazone, a selective PPAR{gamma} agonist. Eleven nondiabetic obese subjects and 11 obese diabetic subjects were each given 4 mg of rosiglitazone daily for a period of 6 wk. Fasting blood samples were obtained at 0, 1, 2, 4, 6, and 12 wk (6 wk after the cessation of rosiglitazone). Eight obese subjects and five obese diabetic subjects were also included in the study as control groups. Fasting blood samples were obtained from the control groups at 0, 1, 2, 4, and 6 wk only. Nuclear factor {kappa}B (NF{kappa}B)-binding activity in mononuclear cells, plasma monocyte chemoattractant protein-1 (MCP-1), TNF-{alpha}, soluble intercellular adhesion molecule-1, C-reactive protein (CRP), and serum amyloid A (SAA) were measured.

Blood glucose concentration changed significantly at 6 wk only in the obese diabetic subjects after rosiglitazone treatment for 6 wk, whereas insulin concentration decreased significantly at 6 wk in both groups. NF{kappa}B-binding activity in mononuclear cell nuclear extract fell in both obese and obese diabetic subjects (P < 0.02). Rosiglitazone treatment resulted in a reduction in plasma MCP-1 and CRP in both groups (P < 0.05). Plasma TNF-{alpha} and SAA concentrations were inhibited significantly in the obese group (P < 0.05) but not in the obese diabetic subjects. NF{kappa}B-binding activity and plasma MCP-1, CRP, SAA, and TNF-{alpha} did not change in the obese and obese diabetic control groups.

We conclude that rosiglitazone, a selective PPAR{gamma} agonist, exerts an antiinflammatory effect at the cellular and molecular level, and in plasma. These observations may have implications for atherogenesis in the long term in subjects treated with rosiglitazone and possibly other thiazolidinediones.

This work was supported by Glaxo SmithKline and the McGowan Charitable Fund.

Abbreviations: BMI, Body mass index; CRP, C-reactive protein; ICAM-1, intercellular adhesion molecule-1; I{kappa}B, inhibitor {kappa}B; MCP-1, monocyte chemoattractant protein-1; MNC, mononuclear cell; NF{kappa}B, nuclear factor {kappa}B; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; sICAM-1, soluble ICAM-1.




This article has been cited by other articles:


Home page
 Diabetes CareHome page
S. E. Kahn, S. M. Haffner, G. Viberti, W. H. Herman, J. M. Lachin, B. G. Kravitz, D. Yu, G. Paul, R. R. Holman, B. Zinman, et al.
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT)
Diabetes Care, January 1, 2010; 33(1): 177 - 183.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. G. Naik, B. M. Brooks-Worrell, and J. P. Palmer
Latent Autoimmune Diabetes in Adults
J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4635 - 4644.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Su, G. M. Coudriet, D. Hyun Kim, Y. Lu, G. Perdomo, S. Qu, S. Slusher, H. M. Tse, J. Piganelli, N. Giannoukakis, et al.
FoxO1 Links Insulin Resistance to Proinflammatory Cytokine IL-1{beta} Production in Macrophages
Diabetes, November 1, 2009; 58(11): 2624 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. M. Moreno-Navarrete, F. J. Ortega, J. Bassols, W. Ricart, and J. M. Fernandez-Real
Decreased Circulating Lactoferrin in Insulin Resistance and Altered Glucose Tolerance as a Possible Marker of Neutrophil Dysfunction in Type 2 Diabetes
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 4036 - 4044.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Lamontagne, E. Pepin, M.-L. Peyot, E. Joly, N. B. Ruderman, V. Poitout, S. R. M. Madiraju, C. J. Nolan, and M. Prentki
Pioglitazone Acutely Reduces Insulin Secretion and Causes Metabolic Deceleration of the Pancreatic {beta}-Cell at Submaximal Glucose Concentrations
Endocrinology, August 1, 2009; 150(8): 3465 - 3474.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. Jiao, Q. Chen, S. Shah, J. Du, B. Tao, I. Tzameli, W. Yan, and H. Xu
Obesity-Related Upregulation of Monocyte Chemotactic Factors in Adipocytes: Involvement of Nuclear Factor-{kappa}B and c-Jun NH2-Terminal Kinase Pathways
Diabetes, January 1, 2009; 58(1): 104 - 115.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
H. Shen, E. Oesterling, A. Stromberg, M. Toborek, R. MacDonald, and B. Hennig
Zinc Deficiency Induces Vascular Pro-Inflammatory Parameters Associated with NF-{kappa}B and PPAR Signaling
J. Am. Coll. Nutr., October 1, 2008; 27(5): 577 - 587.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Orasanu, O. Ziouzenkova, P. R. Devchand, V. Nehra, O. Hamdy, E. S. Horton, and J. Plutzky
The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice
J. Am. Coll. Cardiol., September 2, 2008; 52(10): 869 - 881.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C. H. Chen, P. H. Wang, B. H. Liu, H. H. Hsu, H. J. Mersmann, and S. T. Ding
Serum Amyloid A Protein Regulates the Expression of Porcine Genes Related to Lipid Metabolism
J. Nutr., April 1, 2008; 138(4): 674 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Lombardi, G. Cantini, E. Piscitelli, S. Gelmini, M. Francalanci, T. Mello, E. Ceni, G. Varano, G. Forti, M. Rotondi, et al.
A New Mechanism Involving ERK Contributes to Rosiglitazone Inhibition of Tumor Necrosis Factor-{alpha} and Interferon-{gamma} Inflammatory Effects in Human Endothelial Cells
Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 718 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
P. Dandona
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Tesse, G. Al-Massarani, R. Wangensteen, S. Reitenbach, M. C. Martinez, and R. Andriantsitohaina
Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist, Prevents Microparticle-Induced Vascular Hyporeactivity through the Regulation of Proinflammatory Proteins
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 539 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Fleischman, S. E. Shoelson, R. Bernier, and A. B. Goldfine
Salsalate Improves Glycemia and Inflammatory Parameters in Obese Young Adults
Diabetes Care, February 1, 2008; 31(2): 289 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Brodbeck, M. E. Balestra, A. M. Saunders, A. D. Roses, R. W. Mahley, and Y. Huang
Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons
PNAS, January 29, 2008; 105(4): 1343 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. T. A. Nguyen, S. Favelyukis, A.-K. Nguyen, D. Reichart, P. A. Scott, A. Jenn, R. Liu-Bryan, C. K. Glass, J. G. Neels, and J. M. Olefsky
A Subpopulation of Macrophages Infiltrates Hypertrophic Adipose Tissue and Is Activated by Free Fatty Acids via Toll-like Receptors 2 and 4 and JNK-dependent Pathways
J. Biol. Chem., November 30, 2007; 282(48): 35279 - 35292.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
C. Schindler
Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. Bascil Tutuncu, and N. Guvener Demirag
Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3523 - 3530.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
S.-K. Kim, K.-Y. Hur, H.-J. Kim, W.-S. Shim, C.-W. Ahn, S.-W. Park, Y.-W. Cho, S.-K. Lim, H.-C. Lee, and B.-S. Cha
The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment
Eur. J. Endocrinol., August 1, 2007; 157(2): 167 - 174.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Mittermayer, G. Schaller, J. Pleiner, K. Krzyzanowska, S. Kapiotis, M. Roden, and M. Wolzt
Rosiglitazone Prevents Free Fatty Acid-Induced Vascular Endothelial Dysfunction
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2574 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
A. H Barnett
Summarising the use of thiazolidinediones with insulin
The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 75 - 80.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire
Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism
Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona
Low-Dose Rosiglitazone Exerts an Antiinflammatory Effect with an Increase in Adiponectin Independently of Free Fatty Acid Fall and Insulin Sensitization in Obese Type 2 Diabetics
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3553 - 3558.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Shadid, C. D. A. Stehouwer, and M. D. Jensen
Diet/Exercise Versus Pioglitazone: Effects of Insulin Sensitization with Decreasing or Increasing Fat Mass on Adipokines and Inflammatory Markers
J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3418 - 3425.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. I. Iruretagoyena, S. E. Sepulveda, J. P. Lezana, M. Hermoso, M. Bronfman, M. A. Gutierrez, S. H. Jacobelli, and A. M. Kalergis
Inhibition of Nuclear Factor-{kappa}B Enhances the Capacity of Immature Dendritic Cells to Induce Antigen-Specific Tolerance in Experimental Autoimmune Encephalomyelitis
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 59 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. Sourij, R. Zweiker, and T. C. Wascher
Effects of Pioglitazone on Endothelial Function, Insulin Sensitivity, and Glucose Control in Subjects With Coronary Artery Disease and New-Onset Type 2 Diabetes
Diabetes Care, May 1, 2006; 29(5): 1039 - 1045.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Sell, D. Dietze-Schroeder, U. Kaiser, and J. Eckel
Monocyte Chemotactic Protein-1 Is a Potential Player in the Negative Cross-Talk between Adipose Tissue and Skeletal Muscle
Endocrinology, May 1, 2006; 147(5): 2458 - 2467.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
T. W. JUNG, J. Y. LEE, W. S. SHIM, E. S. KANG, S. K. KIM, C. W. AHN, H. C. LEE, and B. S. CHA
ROSIGLITAZONE RELIEVES ACUTE ETHANOL-INDUCED HANGOVER IN SPRAGUE-DAWLEY RATS
Alcohol Alcohol., May 1, 2006; 41(3): 231 - 235.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Marfella, M. D'Amico, K. Esposito, A. Baldi, C. Di Filippo, M. Siniscalchi, F. C. Sasso, M. Portoghese, F. Cirillo, F. Cacciapuoti, et al.
The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment
Diabetes, March 1, 2006; 55(3): 622 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
R. Agarwal
Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy
Am J Physiol Renal Physiol, March 1, 2006; 290(3): F600 - F605.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. K. Koh, S. H. Han, and M. J. Quon
Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
U. Singh, J. Tabibian, S. K. Venugopal, S. Devaraj, and I. Jialal
Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents
Clin. Chem., December 1, 2005; 51(12): 2252 - 2256.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. Mahmud and J. Feely
Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension
Hypertension, November 1, 2005; 46(5): 1118 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. P.H. van Wijk, E. J.P. de Koning, M. C. Cabezas, J. op't Roodt, J. Joven, T. J. Rabelink, and A. I. Hoepelman
Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy: A Randomized Trial
Ann Intern Med, September 6, 2005; 143(5): 337 - 346.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
A Consoli and E Devangelio
Thiazolidinediones and inflammation
Lupus, September 1, 2005; 14(9): 794 - 797.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Dhindsa, D. Tripathy, N. Sanalkumar, S. Ravishankar, H. Ghanim, A. Aljada, and P. Dandona
Free Fatty Acid-Induced Insulin Resistance in the Obese Is Not Prevented by Rosiglitazone Treatment
J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5058 - 5063.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. C. Calkin, J. M. Forbes, C. M. Smith, M. Lassila, M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen
Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1903 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
I. Tarkun, B. Cetinarslan, E. Turemen, T. Sahin, Z. Canturk, and B. Komsuoglu
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome
Eur. J. Endocrinol., July 1, 2005; 153(1): 115 - 121.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Pfutzner, N. Marx, G. Lubben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst
Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control: Results From the Pioneer Study
J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1925 - 1931.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Kamin, C. Hadigan, M. Lehrke, S. Mazza, M. A. Lazar, and S. Grinspoon
Resistin Levels in Human Immunodeficiency Virus-Infected Patients with Lipoatrophy Decrease in Response to Rosiglitazone
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3423 - 3426.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. M. Bruun, A. S. Lihn, S. B. Pedersen, and B. Richelsen
Monocyte Chemoattractant Protein-1 Release Is Higher in Visceral than Subcutaneous Human Adipose Tissue (AT): Implication of Macrophages Resident in the AT
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2282 - 2289.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg
Metabolic Syndrome: A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation
Circulation, March 22, 2005; 111(11): 1448 - 1454.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
V. A. Fonseca, J. Diez, and D. B. McNamara
Decreasing Restenosis Following Angioplasty: The potential of peroxisome proliferator-activated receptor {gamma} agonists
Diabetes Care, November 1, 2004; 27(11): 2764 - 2766.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Dandona, A. Aljada, H. Ghanim, P. Mohanty, C. Tripathy, D. Hofmeyer, and A. Chaudhuri
Increased Plasma Concentration of Macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in Mononuclear Cells in the Obese and the Suppressive Action of Metformin
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5043 - 5047.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. Wilding
Obesity treatment: the key to managing the type 2 diabetes timebomb?
The British Journal of Diabetes & Vascular Disease, July 1, 2004; 4(4): 217 - 219.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society